Indian Journal of Critical Care Medicine

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  28 (2024)
Volume  27 (2023)
Volume  26 (2022)
Volume  25 (2021)
Volume  24 (2020)
Volume  23 (2019)
Volume  22 (2018)
Volume  21 (2017)
Volume  20 (2016)
Volume  19 (2015)
Volume  18 (2014)
Volume  17 (2013)
Volume  16 (2012)
Volume  15 (2011)
Volume  14 (2010)
Volume  13 (2009)
Volume  12 (2008)
Volume  11 (2007)
Volume  10 (2006)
Volume  9 (2005)
Volume  8 (2004)
Related articles

VOLUME 21 , ISSUE 11 ( 2017 ) > List of Articles

RESEARCH ARTICLE

Treatment of acute kidney injury complicating septic shock with EMiC2 high-cutoff hemofilter: Case series

King-Chung Chan, Wing-Wa Yan, Hoi-Ping Shum, Tak Chan

Keywords : Acute kidney injury, high-cutoff hemofilter, septic shock

Citation Information : Chan K, Yan W, Shum H, Chan T. Treatment of acute kidney injury complicating septic shock with EMiC2 high-cutoff hemofilter: Case series. Indian J Crit Care Med 2017; 21 (11):751-757.

DOI: 10.4103/ijccm.IJCCM_338_17

License: CC BY-ND 3.0

Published Online: 01-01-2019

Copyright Statement:  Copyright © 2017; The Author(s).


Abstract

Introduction: Extracorporeal blood purification therapies have been proposed to improve outcomes of patients with severe sepsis, with or without accompanying acute kidney injury (AKI), by removal of excessive inflammatory mediators. Materials and Methods: We report our experience with EMiC2 high-cutoff continuous venovenous hemofiltration/hemodialysis (HCO-CVVH/HD) in seven patients with AKI complicating septic shock. Results: The median treatment duration was 71 h, and the procedure was well tolerated. Trough serum albumin level of 20 g/L was observed after 2 h of treatment and none of the patients required albumin supplement. The hospital mortality rate was 29%, which appeared more favorable than the predicted mortality of 60%–78% based on disease severity scores. Circulating levels of interleukin-6 (IL-6), IL-10, and tumor necrosis factor-alpha improved over time. Conclusion: This case series shows that HCO-CVVH/CVVHD using EMiC2 hemofilter may provide good cytokine modulation, when used along with good quality standard sepsis therapy. A further large-scale prospective randomized controlled trial is recommended.

PDF Share
  1. Prince LR, Whyte MK, Sabroe I, Parker LC. The role of TLRs in neutrophil activation. Curr Opin Pharmacol 2011;11:397-403.
  2. Nakayama H, Kurokawa K, Lee BL. Lipoproteins in bacteria: Structures and biosynthetic pathways. FEBS J 2012;279:4247-68.
  3. Zarbock A, Gomez H, Kellum JA. Sepsis-induced acute kidney injury revisited: Pathophysiology, prevention and future therapies. Curr Opin Crit Care 2014;20:588-95.
  4. Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med 2013;369:840-51.
  5. Gomez H, Ince C, De Backer D, Pickkers P, Payen D, Hotchkiss J, et al. Aunified theory of sepsis-induced acute kidney injury: Inflammation, microcirculatory dysfunction, bioenergetics, and the tubular cell adaptation to injury. Shock 2014;41:3-11.
  6. Wang C, Sun J, Zheng J, Guo L, Ma H, Zhang Y, et al. Low-dose hydrocortisone therapy attenuates septic shock in adult patients but does not reduce 28-day mortality: A meta-analysis of randomized controlled trials. Anesth Analg 2014;118:346-57.
  7. Kalil AC, Sun J. Low-dose steroids for septic shock and severe sepsis: The use of Bayesian statistics to resolve clinical trial controversies. Intensive Care Med 2011;37:420-9.
  8. Alejandria MM, Lansang MA, Dans LF, Mantaring JB 3rd. Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. Cochrane Database Syst Rev 2013;16:CD001090.
  9. Bernard GR, Francois B, Mira JP, Vincent JL, Dellinger RP, Russell JA, et al. Evaluating the efficacy and safety of two doses of the polyclonal anti-tumor necrosis factor-α fragment antibody AZD9773 in adult patients with severe sepsis and/or septic shock: Randomized, double-blind, placebo-controlled phase IIb study. Crit Care Med 2014;42:504-11.
  10. Ronco C, Tetta C, Mariano F, Wratten ML, Bonello M, Bordoni V, et al. Interpreting the mechanisms of continuous renal replacement therapy in sepsis: The peak concentration hypothesis. Artif Organs 2003;27:792-801.
  11. Rimmelé T, Kellum JA. Clinical review: Blood purification for sepsis. Crit Care 2011;15:205.
  12. Cole L, Bellomo R, Hart G, Journois D, Davenport P, Tipping P, et al. Aphase II randomized, controlled trial of continuous hemofiltration in sepsis. Crit Care Med 2002;30:100-6.
  13. Payen D, Mateo J, Cavaillon JM, Fraisse F, Floriot C, Vicaut E, et al. Impact of continuous venovenous hemofiltration on organ failure during the early phase of severe sepsis: A randomized controlled trial. Crit Care Med 2009;37:803-10.
  14. Haase M, Bellomo R, Morgera S, Baldwin I, Boyce N. High cut-off point membranes in septic acute renal failure: A systematic review. Int J Artif Organs 2007;30:1031-41.
  15. Morgera S, Rocktäschel J, Haase M, Lehmann C, von Heymann C, Ziemer S, et al. Intermittent high permeability hemofiltration in septic patients with acute renal failure. Intensive Care Med 2003;29:1989-95.
  16. Morgera S, Haase M, Kuss T, Vargas-Hein O, Zuckermann-Becker H, Melzer C, et al. Pilot study on the effects of high cutoff hemofiltration on the need for norepinephrine in septic patients with acute renal failure. Crit Care Med 2006;34:2099-104.
  17. Haase M, Bellomo R, Baldwin I, Haase-Fielitz A, Fealy N, Davenport P, et al. Hemodialysis membrane with a high-molecular-weight cutoff and cytokine levels in sepsis complicated by acute renal failure: A phase 1 randomized trial. Am J Kidney Dis 2007;50:296-304.
  18. Villa G, Zaragoza JJ, Sharma A, Neri M, De Gaudio AR, Ronco C, et al. Cytokine removal with high cut-off membrane: Review of literature. Blood Purif 2014;38:167-73.
  19. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving sepsis campaign: International guidelines for management of sepsis and septic shock: 2016. Crit Care Med 2017;45:486-552.
  20. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008;36:296-327.
  21. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013;41:580-637.
  22. Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract 2012;120:c179-84.
  23. Shum HP, Yan WW, Chan TM. Risks and benefits of citrate anticoagulation for continuous renal replacement therapy. Hong Kong Med J 2015;21:149-54.
  24. Zimmerman JE, Kramer AA, McNair DS, Malila FM. Acute physiology and chronic health evaluation (APACHE) IV: Hospital mortality assessment for today's critically ill patients. Crit Care Med 2006;34:1297-310.
  25. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, et al. The SOFA (Sepsis-related organ failure assessment) score to describe organ dysfunction/failure. On behalf of the working group on sepsis-related problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996;22:707-10.
  26. Patel BM, Chittock DR, Russell JA, Walley KR. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 2002;96:576-82.
  27. Yaroustovsky M, Abramyan M, Krotenko N, Popov D, Plyushch M, Rogalskaya E, et al. Combined extracorporeal therapy for severe sepsis in patients after cardiac surgery. Blood Purif 2014;37:39-46.
  28. Schmidt JJ, Hafer C, Clajus C, Hadem J, Beutel G, Schmidt BM, et al. New high-cutoff dialyzer allows improved middle molecule clearance without an increase in albumin loss: A clinical crossover comparison in extended dialysis. Blood Purif 2012;34:246-52.
  29. Schmidt JJ, Hafer C, Spielmann J, Hadem J, Schönenberger E, Schmidt BM, et al. Removal characteristics and total dialysate content of glutamine and other amino acids in critically ill patients with acute kidney injury undergoing extended dialysis. Nephron Clin Pract 2014;126:62-6.
  30. Chelazzi C, Villa G, D'Alfonso MG, Mancinelli P, Consales G, Berardi M, et al. Hemodialysis with high cut-off hemodialyzers in patients with multi-drug resistant gram-negative sepsis and acute kidney injury: A Retrospective, case-control study. Blood Purif 2016;42:186-93.
  31. Villa G, D'Alfonso MG, Di Maggio P, Berardi M, Chelazzi C, Caldini AL, et al. Role of hemodialysis with high cut-off membranes in a patient with a non-recognized leishmaniasis. Blood Purif 2014;38:239-41.
  32. Honore P, Beck W. High Cut-Off Continuous Veno-Venous Hemodialysis (CVVHD) in Patients Treated for Acute Renal Failure After Systemic Inflammatory Response Syndrome (SIRS)/Septic Shock (HICOSS). 10th ed. Florence, Italy: WFSCICCM; 2009.
  33. Morgera S, Haase M, Rocktäschel J, Böhler T, von Heymann C, Vargas-Hein O, et al. High permeability haemofiltration improves peripheral blood mononuclear cell proliferation in septic patients with acute renal failure. Nephrol Dial Transplant 2003;18:2570-6.
  34. Morgera S, Slowinski T, Melzer C, Sobottke V, Vargas-Hein O, Volk T, et al. Renal replacement therapy with high-cutoff hemofilters: Impact of convection and diffusion on cytokine clearances and protein status. Am J Kidney Dis 2004;43:444-53.
  35. Namekawa K, Fukuda M, Matsuda M, Yagi Y, Yamamoto K, Sakai K, et al. Nanotechnological characterization of human serum albumin adsorption on wet synthetic polymer dialysis membrane surfaces. ASAIO J 2009;55:236-42.
  36. Naka T, Haase M, Bellomo R. 'Super high-flux' or 'high cut-off' hemofiltration and hemodialysis. Contrib Nephrol 2010;166:181-9.
  37. Morgera S, Klonower D, Rocktäschel J, Haase M, Priem F, Ziemer S, et al. TNF-alpha elimination with high cut-off haemofilters: A feasible clinical modality for septic patients? Nephrol Dial Transplant 2003;18:1361-9.
  38. Uchino S, Bellomo R, Goldsmith D, Davenport P, Cole L, Baldwin I, et al. Super high flux hemofiltration: A new technique for cytokine removal. Intensive Care Med 2002;28:651-5.
  39. Uchino S, Bellomo R, Goldsmith D, Davenport P, Cole L, Baldwin I, et al. Cytokine removal with a large pore cellulose triacetate filter: An ex vivo study. Int J Artif Organs 2002;25:27-32.
  40. Bordoni V, Bolgan I, Brendolan A, Crepaldi C, Gastaldon F, D'intini V, et al. Caspase-3 and -8 activation and cytokine removal with a novel cellulose triacetate super-permeable membrane in anin vitro sepsis model. Int J Artif Organs 2003;26:897-905.
  41. Atan R, Crosbie D, Bellomo R. Techniques of extracorporeal cytokine removal: A systematic review of the literature. Blood Purif 2012;33:88-100.
  42. Joannidis M, Oudemans-van Straaten HM. Clinical review: Patency of the circuit in continuous renal replacement therapy. Crit Care 2007;11:218.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.